CROs Partner to Map Cancer’s Complexity, Speeding Drug Development

ST. LOUIS, MO – May 27, 2026 – In a strategic move aimed at accelerating the fight against cancer, two specialized contract research organizations (CROs) announced an expanded partnership today that promises to untangle the complex biology of tumors and streamline the path from laboratory to clinic. TD2 Oncology, a global leader in cancer drug development, and Panome Bio, a cutting-edge multi-omics laboratory, are combining their distinct expertise to offer a single, integrated framework for oncology research.

This collaboration directly addresses one of the most significant hurdles in modern medicine: translating the massive volumes of biological data generated in research into effective, life-saving therapies. By providing drug developers with a seamless program that connects preclinical and clinical trial management with comprehensive molecular analysis, the partnership aims to deliver a more holistic understanding of how new cancer drugs work, why they sometimes fail, and who they are most likely to help.

A New Blueprint for Cancer Drug Development

The development of a new cancer therapy is a long and arduous journey, often hampered by a fragmented understanding of a tumor's intricate molecular landscape. Researchers may see that a drug shrinks a tumor in a lab model, but the underlying biological reasons can remain a black box. This partnership seeks to illuminate that box by integrating Panome Bio's deep multi-omics capabilities—including metabolomics, proteomics, transcriptomics, and exposomics—directly into the proven drug development ecosystem of TD2 Oncology.

Multi-omics is an approach that simultaneously analyzes multiple layers of biological information. Rather than just looking at a cell's genes (genomics), it examines the proteins they produce (proteomics), the metabolic processes they fuel (metabolomics), and how genes are expressed (transcriptomics). This provides a dynamic, multi-dimensional snapshot of a tumor's activity.

"Modern oncology research generates enormous amounts of biological data spanning model development through clinical trials, but translating those findings into a deeper molecular understanding remains a major challenge," said Edward Weinstein, CEO of Panome Bio. "Working with TD2 allows us to pair their expertise across translational and clinical oncology with comprehensive multi-omics profiling. This will help to better characterize therapeutic response and connect biology across every stage of development."

By embedding this detailed molecular analysis throughout the entire drug development pipeline—from initial studies in preclinical models to human clinical trials—researchers can now draw direct lines between a therapeutic outcome and the complex biological data that explains it. This integrated approach is designed to accelerate discovery and reduce the costly late-stage failures that plague the pharmaceutical industry.

Uniting Specialized Expertise in a Competitive Market

The collaboration is also a significant strategic maneuver in the highly competitive CRO industry, where specialization and consolidation are becoming key differentiators. TD2 Oncology has built a reputation over two decades for its singular focus on cancer, offering a comprehensive suite of services from over 400 preclinical tumor models to the management of early-phase human trials. Panome Bio, founded in 2022 on a scientific foundation from Washington University in St. Louis, represents the next generation of specialized analytical labs, bringing advanced mass spectrometry and data analysis to the forefront.

By joining forces, the two companies create a unique value proposition that few competitors can match: an end-to-end oncology solution powered by elite molecular profiling.

"Our focus has always been optimizing oncology programs in moving efficiently from translational development into the clinic," stated Stephen Gately, CEO of TD2 Oncology. "No other oncology CRO can offer this combination of translational and clinical expertise alongside this depth of molecular profiling. This partnership gives drug developers a direct connection between therapeutic outcomes and the molecular data needed to understand them."

This synergy is particularly critical for biotech and pharmaceutical companies that may lack the extensive internal infrastructure to conduct such complex, integrated studies. Instead of juggling multiple vendors for preclinical work, clinical trial management, and specialized bioanalysis, they can now access these services through a single, coordinated program, potentially saving time and resources while ensuring data consistency from start to finish.

From Big Data to Better Biomarkers

At the heart of this partnership is the quest for better biomarkers—biological signatures that can predict how a patient will respond to a specific treatment. Identifying robust biomarkers is the cornerstone of precision medicine, allowing doctors to select the right drug for the right patient at the right time. However, these signatures are often hidden within complex webs of biological interactions that cannot be seen through a single lens.

By integrating multiple 'omics' layers, the collaboration enables researchers to uncover subtle patterns associated with treatment sensitivity, resistance, or toxicity. For example, a drug's effectiveness might not be determined by a single gene mutation but by a combination of protein activity and metabolic shifts within the tumor. The combined expertise of TD2 and Panome Bio is designed to identify these complex signatures.

Crucially, Panome Bio's laboratory is CLIA-certified (Clinical Laboratory Improvement Amendments), a federal standard ensuring the quality and validity of human laboratory testing. This certification is non-negotiable for generating data that can be used to make decisions in clinical trials and for submissions to regulatory bodies like the FDA. It ensures that the molecular insights gained are not just academically interesting but clinically actionable.

This capability is vital for designing smarter, biomarker-driven clinical trials. Instead of enrolling a broad patient population, trials can be designed to include only those patients whose tumors have the specific molecular profile that a drug is designed to target, increasing the likelihood of success and potentially shortening development timelines.

The Path to Personalized Patient Care

Ultimately, the impact of this collaboration is intended to be felt by cancer patients. The move away from a "one-size-fits-all" approach to treatment depends entirely on a deeper understanding of individual tumor biology. By providing a more complete picture of why some treatments work and others fail, this partnership aims to accelerate the development of more effective, personalized therapies.

For patients, this could mean a greater chance of being matched to a clinical trial for a drug that is highly likely to work for their specific cancer. It could also lead to new strategies for overcoming drug resistance, a common and devastating challenge in oncology. When a tumor stops responding to a treatment, integrated multi-omics analysis can help pinpoint the molecular escape routes it has developed, guiding the next line of therapy.

The services offered through this partnership are available immediately, signaling a new and more integrated era in the long and complex process of developing the next generation of cancer treatments.